Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient

Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.

Original languageEnglish
Pages (from-to)726-728
Number of pages3
JournalInternational Journal of STD and AIDS
Volume28
Issue number7
DOIs
Publication statusPublished - 2017

Keywords

  • Atazanavir
  • dolutegravir
  • maintenance antiretroviral therapy
  • pharmacokinetics

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient'. Together they form a unique fingerprint.

Cite this